The axillary hyperhidrosis treatments market share was anticipated to be worth US$ 1.6 billion in 2022 and is projected to increase to US$ 3.3 billion by 2033, according to a recent industry analysis published by Future Market Insights (FMI).
Axillary hyperhidrosis is a common condition that affects Millions of people worldwide, causing embarrassment and discomfort. There are various non-invasive and minimally invasive treatments available in the market that uses advanced technology to target the sweat glands in the underarm area, providing long-lasting relief from excessive sweating. Botox injections and miraDry are such procedures that give satisfactory results with minimalistic or no pain while treating the patients. This has resulted in higher uptake from patients in recent years, as a result, owing to this trend, the market is expected to expand in the future as well.
The prevalence of axillary hyperhidrosis is increasing worldwide, which is driving the demand for effective treatment options.
As awareness of axillary hyperhidrosis is growing, more patients are being diagnosed and seeking treatment, which is causing the market for axillary hyperhidrosis treatment to further expand. Advances in technology have led to the development of new and innovative treatment options, such as minimally invasive procedures and non-invasive devices, which are driving the growth of the axillary hyperhidrosis treatment market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-6026
Many patients with axillary hyperhidrosis seek treatment for cosmetic reasons, as excessive underarm sweating can cause embarrassment and social stigma. This is driving the demand for cosmetic treatments that address axillary hyperhidrosis. Combination therapies, which use multiple treatment modalities to address axillary hyperhidrosis, are becoming increasingly popular among patients and healthcare providers. This is driving the growth of the market for combination therapies for axillary hyperhidrosis treatment.
Overall, these factors are contributing to the growth of the axillary hyperhidrosis treatment market, and are expected to continue to drive demand for effective and innovative treatment options in the coming years.
Key Takeaways:
Drug therapy is the leading segment of treatment among patients and professionals, and held about 62.7% market share in 2022, due to its non-invasive nature and high efficacy in reducing excessive sweating in patients.
- By distribution channel, the retail pharmacies dominated the global axillary hyperhidrosis treatment market withholding the total market share of about 34.2% by the end of 2022, owing to the convenience and ease of accessibility to a range of products from OTC/off-label products to licensed products.
- By region, North America is leading in the global axillary hyperhidrosis treatment market and is expected to continue to do so with a projected CAGR rate of 5.4% during the forecasted years.
“Increasing adoption of combination therapies and growing awareness and diagnosis of the condition to create the lucrative potential for the market to grow,” says an analyst at Future Market Insights (FMI).
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-6026
Market Competition:
Key participants in the market for axillary hyperhidrosis treatment employ expansion of the company through acquisitions, mergers, collaborations, and partnerships. Key players are concentrating on strategies like expanding sales and implementing new technology for the creation of novel products.
- In December 2021, Sientra, Inc. announced that it had entered into an agreement to acquire all of the assets related to the novel fat grafting technology from AuraGen Aesthetic, LLC.
- In August 2022, GSK plc announced that it had acquired Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts.
Key Players:
- Allergan plc. (AbbVie)
- Journey Medical Corporation (Dermira, Inc.)
- Riemann A/S (Orkla)
- SweatBlock
- Certain Dri
- miraDry, Inc. (Sientra)
- STRATUS PHARMACEUTICALS INC.
- Duradry
- Persn & Covey
- GlaxoSmithKline Plc.
- Carpe
- SweatStop® International
- CORAD Healthcare
- ZeroSweat
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the axillary hyperhidrosis treatment market in its latest study, presenting a historical demand assessment of 2017 to 2022 and projections for 2023 to 2033. The global axillary hyperhidrosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The research study is based on treatment – [drug therapy (antiperspirants (both OTC & Rx) (antiperspirants spray, antiperspirants roll-on, antiperspirants wipes, antiperspirants lotion & gel) antihypertensive drugs, anticholinergic agents, alpha-adrenergic agonists), botulinum toxins, medicated wipes, and microwave therapy], distribution channel – (hospitals, general physician’s clinics, retail pharmacy chains, and drug stores (online sales and manufacturer websites)), across seven regions of the world.
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-6026
Key Segments :
By Treatment:
- Drug Therapy
- Antiperspirants (Both OTC & Rx)
- Antiperspirants Spray
- Antiperspirants Roll-On
- Antiperspirants Wipes
- Antiperspirants Lotion & Gel
- Antihypertensive Drugs
- Anticholinergic Agents
- Alpha-Adrenergic Agonists
- Antiperspirants (Both OTC & Rx)
- Botulinum Toxins
- Medicated Wipes
- Microwave Therapy
By Distribution Channel:
- Hospitals
- General Physician’s Clinics
- Retail Pharmacy Chains
- Drug Stores
- Online Sales
- Manufacturer websites
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
